The Experts below are selected from a list of 744 Experts worldwide ranked by ideXlab platform
Klas Bergenheim - One of the best experts on this subject based on the ideXlab platform.
-
Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration
2016Co-Authors: Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with ther-apy Escalation classically initiated within a ‘‘failure-based’ ’ regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, control-ling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, comparing a sodium/ glucose cotransporter 2 inhibitor v. sulfonylurea added to metforminmonotherapy. Results. Lower Thresholds are asso-ciated with a shorter time spent on monotherapy, ranging from 1.1 years (Escalation at 6.5%) to 13 years (Escalation at 9.0%) and an increase in total lifetime cost of therapy. Treatment-related disutility is minimized with higher thresh-olds because progression to insulin is delayed. Using metfor-min combined with either dapagliflozin or a sulfonylurea to illustrate lower baseline HbA1c and/or higher therapy esca-lation Thresholds was associated with increased cost-effec-tiveness ratios, driven by a longer duration of therapy. Discussion. A marked difference in treatment cost-effective-ness was demonstrated when comparing routine clinical practice with guideline-advocated therapy Escalation. This is important to both health care professionals and the wider health economic community with respect to understanding the true cost-effectiveness profile of any particular T2DM therapy option. Key words: decision aids; internal medi-cine; provider decision making; cost-effectiveness analysis
-
Estimating Cost-Effectiveness in Type 2 Diabetes The Impact of Treatment Guidelines and Therapy Duration
Medical decision making : an international journal of the Society for Medical Decision Making, 2015Co-Authors: Phil Mcewan, Jason Gordon, Marc Evans, Thomas J. Ward, Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with therapy Escalation classically initiated within a “failure-based” regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, controlling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, c...
Hayley Bennett - One of the best experts on this subject based on the ideXlab platform.
-
Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration
2016Co-Authors: Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with ther-apy Escalation classically initiated within a ‘‘failure-based’ ’ regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, control-ling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, comparing a sodium/ glucose cotransporter 2 inhibitor v. sulfonylurea added to metforminmonotherapy. Results. Lower Thresholds are asso-ciated with a shorter time spent on monotherapy, ranging from 1.1 years (Escalation at 6.5%) to 13 years (Escalation at 9.0%) and an increase in total lifetime cost of therapy. Treatment-related disutility is minimized with higher thresh-olds because progression to insulin is delayed. Using metfor-min combined with either dapagliflozin or a sulfonylurea to illustrate lower baseline HbA1c and/or higher therapy esca-lation Thresholds was associated with increased cost-effec-tiveness ratios, driven by a longer duration of therapy. Discussion. A marked difference in treatment cost-effective-ness was demonstrated when comparing routine clinical practice with guideline-advocated therapy Escalation. This is important to both health care professionals and the wider health economic community with respect to understanding the true cost-effectiveness profile of any particular T2DM therapy option. Key words: decision aids; internal medi-cine; provider decision making; cost-effectiveness analysis
-
Estimating Cost-Effectiveness in Type 2 Diabetes The Impact of Treatment Guidelines and Therapy Duration
Medical decision making : an international journal of the Society for Medical Decision Making, 2015Co-Authors: Phil Mcewan, Jason Gordon, Marc Evans, Thomas J. Ward, Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with therapy Escalation classically initiated within a “failure-based” regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, controlling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, c...
Phil Mcewan - One of the best experts on this subject based on the ideXlab platform.
-
Estimating Cost-Effectiveness in Type 2 Diabetes The Impact of Treatment Guidelines and Therapy Duration
Medical decision making : an international journal of the Society for Medical Decision Making, 2015Co-Authors: Phil Mcewan, Jason Gordon, Marc Evans, Thomas J. Ward, Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with therapy Escalation classically initiated within a “failure-based” regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, controlling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, c...
Jason Gordon - One of the best experts on this subject based on the ideXlab platform.
-
Estimating Cost-Effectiveness in Type 2 Diabetes The Impact of Treatment Guidelines and Therapy Duration
Medical decision making : an international journal of the Society for Medical Decision Making, 2015Co-Authors: Phil Mcewan, Jason Gordon, Marc Evans, Thomas J. Ward, Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with therapy Escalation classically initiated within a “failure-based” regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, controlling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, c...
Marc Evans - One of the best experts on this subject based on the ideXlab platform.
-
Estimating Cost-Effectiveness in Type 2 Diabetes The Impact of Treatment Guidelines and Therapy Duration
Medical decision making : an international journal of the Society for Medical Decision Making, 2015Co-Authors: Phil Mcewan, Jason Gordon, Marc Evans, Thomas J. Ward, Hayley Bennett, Klas BergenheimAbstract:Objectives. Type 2 diabetes mellitus (T2DM) clinical guidelines focus on optimizing glucose control, with therapy Escalation classically initiated within a “failure-based” regimen. Within many diabetes models, HbA1c therapy Escalation Thresholds play a pivotal role, controlling duration of therapy and, consequently, incremental costs and benefits. The objective of this study was to assess the relationship between therapy Escalation Threshold and time to therapy Escalation on predicted cost-effectiveness of T2DM treatments. Methods. This study used the Cardiff Diabetes Model to illustrate the relationship between costs and health outcomes associated with first-, second-, and third-line therapy as a function of time on each. Data from routine clinical practice were used to contrast predicted costs and health outcomes associated with guideline therapy Escalation Thresholds compared with clinical practice. The impact of baseline HbA1c and therapy Escalation Thresholds on cost-effectiveness was investigated, c...